HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole.

Abstract
A bovine in-vitro model was developed to investigate device-induced thromboembolism (TE) and its pharmacological intervention, using a stent as a prototype device. Emboli were assessed continuously using a light-scattering microemboli detector (LSMD). Thrombus on the stent was assessed gravimetrically at the end of the experiment. The contribution of the stent as the predominant source of detectable thromboemboli in this model was verified by placing LSMD probes upstream and downstream of the stent. The effectiveness of ethylenedinitrilo-tetraacetic-acid (EDTA) and three anti-thrombogenic agents (aspirin, dipyridamole, and tirofiban) for mitigating device-induced TE was also assessed. The results show that 1) the model has potential to study device-induced TE and the efficacy of possible interventional strategies, 2) the LSMD is capable of continuous, non-invasive, real-time assessment of embolism, 3) the assessment of embolization may constitute an important part of evaluating hemocompatibility, 4) tirofiban is effective in reducing both stent-induced thrombosis and embolism above certain concentrations.
AuthorsS Sukavaneshvar, K A Solen, S F Mohammad
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 83 Issue 2 Pg. 322-6 (Feb 2000) ISSN: 0340-6245 [Print] Germany
PMID10739393 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tyrosine
  • Dipyridamole
  • Edetic Acid
  • Tirofiban
  • Aspirin
Topics
  • Animals
  • Anticoagulants (pharmacology)
  • Aspirin (pharmacology)
  • Blood Flow Velocity
  • Cattle
  • Dipyridamole (pharmacology)
  • Dose-Response Relationship, Drug
  • Edetic Acid (pharmacology)
  • Embolism (etiology, prevention & control)
  • Equipment Design
  • Equipment and Supplies (adverse effects)
  • Evaluation Studies as Topic
  • Platelet Aggregation Inhibitors (pharmacology)
  • Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
  • Scattering, Radiation
  • Stents (adverse effects)
  • Thrombosis (etiology, prevention & control)
  • Tirofiban
  • Tyrosine (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: